#AS­CO21: J&J busts out a small up­date for its an­ti­body-TKI com­bo in lung can­cer — whet­ting ap­petites as FDA thinks it over

In a red-hot EGFR-mu­tat­ed non-small cell lung can­cer mar­ket, John­son & John­son thinks it could have a leader in its bis­pe­cif­ic an­ti­body ami­van­tam­ab. But as …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER